There Is Still Room For Aeglea BioTherapeutics Inc. (AGLE) to Improve Its Value – Let’s Wait for Clarity

Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) closed the day trading at $1.26 up 4.13% from the previous closing price of $1.21. In other words, the price has increased by $+0.0500 from its previous closing price. On the day, 593684 shares were traded. AGLE stock price reached its highest trading level at $1.3250 during the session, while it also had its lowest trading level at $1.1600.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report



For a better understanding of AGLE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.70 and its Current Ratio is at 4.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on May 04, 2020, initiated with a Overweight rating and assigned the stock a target price of $12.

On March 21, 2019, JP Morgan started tracking the stock assigning a Overweight rating and target price of $14.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 25 when Souza Marcio bought 90,000 shares for $0.56 per share. The transaction valued at 50,472 led to the insider holds 90,000 shares of the business.

Hanley Jr. Michael Conick bought 28,200 shares of AGLE for $20,022 on Jun 08. The Chief Commercial Officer now owns 36,200 shares after completing the transaction at $0.71 per share. On Mar 16, another insider, Quinn Anthony G., who serves as the President & CEO of the company, bought 80,079 shares for $2.34 each. As a result, the insider paid 187,705 and bolstered with 550,540 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 13.14 while its Price-to-Book (P/B) ratio in mrq is 1.75.

Stock Price History:

Over the past 52 weeks, AGLE has reached a high of $7.09, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is 0.7295, while the 200-Day Moving Average is calculated to be 1.2801.

Shares Statistics:

Over the past 3-months, AGLE traded about 2.78M shares per day on average, while over the past 10 days, AGLE traded about 716.42k shares per day. A total of 94.20M shares are outstanding, with a floating share count of 60.28M. Insiders hold about 0.20% of the company’s shares, while institutions hold 78.80% stake in the company. Shares short for AGLE as of Oct 13, 2022 were 518.73k with a Short Ratio of 0.61M, compared to 645.15k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.85% and a Short% of Float of 0.92%.

Earnings Estimates

Current recommendations for the stock of the company come from 5 analysts. On average, analysts expect EPS of -$0.24 for the current quarter, with a high estimate of -$0.21 and a low estimate of -$0.29, while EPS last year was -$0.31. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.21 and low estimates of -$0.31.

Analysts are recommending an EPS of between -$1.03 and -$1.4 for the fiscal current year, implying an average EPS of -$1.16. EPS for the following year is -$0.85, with 5 analysts recommending between -$0.63 and -$1.1.

Revenue Estimates

A total of 4 analysts have provided revenue estimates for AGLE’s current fiscal year. The highest revenue estimate was $3.24M, while the lowest revenue estimate was $2M, resulting in an average revenue estimate of $2.31M. In the same quarter a year ago, actual revenue was $18.74M, down -87.70% from the average estimate.